Product Description
Olmesartan medoxomil is a nonpeptide angiotensin II receptor antagonist which selectively and competitively inhibits the type 1 angiotensin II receptor without affecting other receptors regulating the cardiovascular system. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/12076183/)
Mechanisms of Action: AT1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Hypertension | Hypertension
Known Adverse Events: Edema | Dizziness | Headache | Spasm | Nasopharyngitis | Pharyngitis | Respiratory Tract Infections | Diarrhea
Company: Cosette Pharmaceuticals
Company Location:
Company CEO:
Additonal Commercial Interests: Daiichi Sankyo
Clinical Description
Countries in Clinic: Australia, Brazil, China
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Hypertension
Phase 2: COVID-19|Kidney Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ATHESA | P3 |
Not yet recruiting |
Hypertension |
2028-04-30 |
|
| HTA5347 | P2 |
Not yet recruiting |
COVID-19 |
2021-04-01 |
|
| 2006-7041-83/hah | P2 |
Not yet recruiting |
Kidney Diseases |
2019-01-28 |
|
| CTR20212325 | P3 |
Not yet recruiting |
Hypertension |
None |